Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. NVDA
2. PSKY
3. META
4. LGND
5. SPY
6. MONC:IM
7. PTON
8. NYXH
9. LXEO
10. MONRY

Go back to Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
(NASDAQ: QNRX) Delayed: 6.98 +0.08 (1.16%)
Previous Close $6.90    52 Week High $ 
Open $6.98    52 Week Low $ 
Day High $7.05    P/E N/A 
Day Low $6.97    EPS $ 
Volume 7,723